Format

Send to:

Choose Destination
See comment in PubMed Commons below
Ther Adv Endocrinol Metab. 2011 Jun;2(3):127-33. doi: 10.1177/2042018811402248.

Sapropterin hydrochloride: enzyme enhancement therapy for phenylketonuria.

Abstract

Phenylketonuria (PKU) is an inherited disorder of amino acid metabolism caused by deficiency of the enzyme phenylalanine hydroxylase (PAH). Historically PKU was a common genetic cause of severe learning difficulties and developmental delay, but with the introduction of newborn screening and early dietary management, it has become a treatable disease and people born with PKU should now have IQs and achievements similar to their peers. Dietary treatment, however, involves lifestyle changes that pervade most aspects of daily life for an individual and their family. A simple pharmacological treatment for PKU would have a great appeal. Sapropterin hydrochloride is a synthetic form of tetrahydrobiopterin, the cofactor for PAH. A proportion of mutant PAH enzymes show enhanced activity in the presence of pharmacological doses of sapropterin and, for some patients with milder forms of PKU, sapropterin can effectively lower plasma phenylalanine levels. This article discusses the potential place for sapropterin in the management of PKU and how this expensive orphan drug is being integrated into patient care in different healthcare systems.

KEYWORDS:

dietary therapy; enzyme enhancement therapy; orphan drugs; phenylketonuria; sapropterin hydrochloride; tetrahydrobiopterin

PMID:
23148178
[PubMed]
PMCID:
PMC3474634
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk